To get ahead of disruption and risk, forward-thinking organizations are turning to unified endpoint management (UEM) ...

Join our daily and weekly newsletters for the latest updates and exclusive content on industry-leading AI coverage. Learn More Attackers are turning to generative AI to hunt for the easiest endpoints ...

Join the event trusted by enterprise leaders for nearly two decades. VB Transform brings together the people building real enterprise AI strategy. Learn more Bad actors continue to capitalize on the ...

Federal agencies across civilian, defense, and financial sectors face growing risks at the endpoint—from nation-state actors ...

A phase 3 trial evaluating benralizumab for the treatment of COPD did not meet its primary endpoint, according to AstraZeneca.

Protecting critical systems calls for a disciplined approach that mirrors battlefield tactics in its emphasis on awareness, ...

MSK played a central role in the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC)’s landmark decision in April 2024 to accept measurable residual disease (MRD) as an ...

Topline data were announced from a phase 3 trial evaluating efzofitimod in patients with pulmonary sarcoidosis.

Acadia Pharmaceuticals shares were halted at $23.80 in premarket trading after the company said top-line results from its Phase 3 trial for ACP-101 missed its primary endpoint.